142 related articles for article (PubMed ID: 1862329)
1. Positive response. Encouraging results in the search for an AIDS vaccine.
Beardsley T
Sci Am; 1991 Aug; 265(2):26. PubMed ID: 1862329
[No Abstract] [Full Text] [Related]
2. Human trials of AIDS vaccines: current status and future directions.
Koff WC; Fauci AS
AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
[No Abstract] [Full Text] [Related]
3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
4. Two additional AIDS vaccines approved for clinical trials.
J Am Osteopath Assoc; 1991 May; 91(5):433. PubMed ID: 2061098
[No Abstract] [Full Text] [Related]
5. Which gp160 vaccine?
Moore J; Lewis GK; Robinson J
Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
[No Abstract] [Full Text] [Related]
6. [AIDS--HIV envelope protein improves vaccination response].
GURTLER L
Fortschr Med; 1991 Dec; 109(35):10-1. PubMed ID: 1774002
[No Abstract] [Full Text] [Related]
7. Prospects for an AIDS vaccine.
Girard M
Cancer Detect Prev; 1990; 14(3):411-3. PubMed ID: 2117487
[TBL] [Abstract][Full Text] [Related]
8. MicroGeneSys drops out of NIH trial for AIDS vaccine.
Macilwain C
Nature; 1993 Mar; 362(6418):277. PubMed ID: 8455703
[No Abstract] [Full Text] [Related]
9. Research indicates rgp 160 provides long-term immunologic protection. Chimpanzee resists HIV challenge more than two years after vaccination.
Crit Care Nurse; 1991 Sep; 11(8):1. PubMed ID: 1893756
[No Abstract] [Full Text] [Related]
10. [AIDS vaccine--its strategies and prospects].
Kitamura T
Nihon Rinsho; 1993 Sep; 51 Suppl():530-5. PubMed ID: 8271432
[No Abstract] [Full Text] [Related]
11. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
[TBL] [Abstract][Full Text] [Related]
12. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
[No Abstract] [Full Text] [Related]
13. Gp160 of commercial HIV western blots is not gp160env. Should criteria for seropositivity be revised?
Fenouillet E; Blanes N; Gluckman JC
AIDS; 1991 Jun; 5(6):770. PubMed ID: 1883550
[No Abstract] [Full Text] [Related]
14. Vaccine compromise.
Nature; 1993 Apr; 362(6421):576. PubMed ID: 8464502
[No Abstract] [Full Text] [Related]
15. Does the HIV envelope induce a chronic graft-versus-host-like disease?
Habeshaw J; Hounsell E; Dalgleish A
Immunol Today; 1992 Jun; 13(6):207-10. PubMed ID: 1627248
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
17. [A potential AIDS vaccine tester].
Fortschr Med; 1988 Jul; 106(22):14-5. PubMed ID: 2851511
[No Abstract] [Full Text] [Related]
18. Vaccination with gp160 in HIV.
Oyaizu N; Chirmule N; Pahwa S
N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
[No Abstract] [Full Text] [Related]
19. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with gp160 in HIV.
Stanberry LR; Bernstein DI; Myers MG
N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748
[No Abstract] [Full Text] [Related]
[Next] [New Search]
